Lack of essential asthma medications in primary care centres in Kuwait

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 5, 2003, Pages 422-425

  Behbehani, Nasser A ^a   Al Yousifi, K ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b Sabah Al Naser Primary Care Centre   (Kuwait)

Author keywords

Asthma; Kuwait; Medications

Indexed keywords

AMINOPHYLLINE; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; FLUTICASONE; HYDROCORTISONE; SALBUTAMOL; STEROID; THEOPHYLLINE;

ARTICLE; ASTHMA; CALCULATION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; EMERGENCY WARD; HUMAN; KUWAIT; PRIMARY HEALTH CARE; PRIORITY JOURNAL;

ANTI-ASTHMATIC AGENTS; ASTHMA; COSTS AND COST ANALYSIS; HUMANS; KUWAIT;

EID: 0037545502     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention report. Bethesda, MD: National Institutes of Health, 2002.
2. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998; 351: 1225-1232.
3. Behbehani N A, Abal A, Syabbalo N C, Abd A A, Shareef E, Al Momen J. Prevalence of asthma, allergic rhinitis, and eczema in 13- to 14-year-old children in Kuwait: an ISAAC study. International Study of Asthma and Allergies in Childhood. Ann Allergy Asthma Immunol 2000; 85: 58-63.
4. Abul A T, Nair P C, Behbehanei N A, Sharma P N. Hospital admissions and death rates from asthma in Kuwait during pre- and post-Gulf War periods. Ann Allergy Asthma Immunol 2001; 86: 465-468.
5. National Institute of Health. International consensus report on diagnosis and treatment of asthma. Bethesda, MD: NHLBI, 1992.
6. National Institute of Health. Global strategy for asthma management and prevention. Bethesda, MD: NHLBI, 1995.
7. Ait-Khaled N, Enarson D A. Management of asthma in adults. Guide for low income countries. Paris, France: IUATLD, 1996.
8. World Health Organization. Recommended initial list of 39 international non-proprietary names for pharmaceutical substances. Geneva: WHO, 1998.
9. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388-392.
10. Laitinen L A, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32-42.
11. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-336.
12. Barnes P J, Pedersen S, Busse W W. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157 (3 Pt 2): S1-S53.
13. Louridas G, Kakoura M, Galanis N, Patakas D, Kastritsi K. Bronchodilatory effect of inhaled versus oral salbutamol in bronchial asthma. Respiration 1983; 44: 439-443.
14. Strannegard I L, Strannegard O. Childhood bronchial asthma in a desert country. Allergy 1990; 45: 327-333.
15. Huse D M, Russell M W, Weiss S T, Hartz S C. Anti-inflammatory therapy reduces total costs of asthma care compared with bronchodilation: the Asthma Outcomes Registry. Am J Manag Care 2000; 6: 1045-1050.
16. Ozminkowski R J, Wang S, Marder W D, Azzolini J, Schutt D. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. Pharmacoeconomics 2000; 18: 253-264.
17. Ait-Khaled N, Auregan G, Bencharif N, et al. Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. Int J Tuberc Lung Dis 2000; 4: 268-271.